Comparative Pharmacology

Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.

Peer-Reviewed Evidence

Differential Analysis

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% vs MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%

Electrolyte

Category A/B

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Electrolyte

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Heparin binds to antithrombin III (ATIII) via a unique pentasaccharide sequence, inducing a conformational change that accelerates ATIII-mediated inactivation of coagulation factors IIa (thrombin), Xa, IXa, XIa, and XIIa. The heparin-ATIII complex primarily inhibits thrombin and factor Xa, with higher molecular weight heparin more effectively inactivating thrombin.

Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.

Clinical Dosing

For therapeutic anticoagulation, administer 18 units/kg/hour intravenous infusion after a bolus of 80 units/kg. For prophylactic dosing, 5000 units subcutaneously every 8 to 12 hours.

1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).

Direct Interaction